Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

NCT06395519 is registered in ClinicalTrials.gov with 858 Therapeutics, Inc. as lead sponsor.

NCT NCT06395519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06395519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Lead sponsor
858 Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 13, 2024
Completion date
December 31, 2026
Enrollment
120 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, brca mutation, brca1 mutation, brca2 mutation, breast cancer, castrate resistant prostate cancer, colorectal cancer, endometrial cancer, epithelial ovarian cancer, er+ breast cancer, gastric cancer, ovarian cancer, prostate cancer